- Home
- ANNX vs BACQ Comparison
ANNX vs BACQ Comparison
Compare ANNX & BACQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- BACQ
- Stock Information
- Founded
- ANNX 2011
- BACQ 2024
- Country
- ANNX United States
- BACQ United States
- Employees
- ANNX N/A
- BACQ N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- BACQ
- Sector
- ANNX Health Care
- BACQ
- Exchange
- ANNX Nasdaq
- BACQ NYSE
- Market Cap
- ANNX 362.4M
- BACQ 333.2M
- IPO Year
- ANNX 2020
- BACQ 2024
- Fundamental
- Price
- ANNX $1.46
- BACQ $10.03
- Analyst Decision
- ANNX Strong Buy
- BACQ
- Analyst Count
- ANNX 5
- BACQ 0
- Target Price
- ANNX $18.67
- BACQ N/A
- AVG Volume (30 Days)
- ANNX 2.2M
- BACQ 211.0K
- Earning Date
- ANNX 05-12-2025
- BACQ 01-01-0001
- Dividend Yield
- ANNX N/A
- BACQ N/A
- EPS Growth
- ANNX N/A
- BACQ N/A
- EPS
- ANNX N/A
- BACQ N/A
- Revenue
- ANNX N/A
- BACQ N/A
- Revenue This Year
- ANNX N/A
- BACQ N/A
- Revenue Next Year
- ANNX N/A
- BACQ N/A
- P/E Ratio
- ANNX N/A
- BACQ $111.40
- Revenue Growth
- ANNX N/A
- BACQ N/A
- 52 Week Low
- ANNX $1.29
- BACQ $9.80
- 52 Week High
- ANNX $7.85
- BACQ $10.07
- Technical
- Relative Strength Index (RSI)
- ANNX 30.77
- BACQ N/A
- Support Level
- ANNX $1.40
- BACQ N/A
- Resistance Level
- ANNX $1.68
- BACQ N/A
- Average True Range (ATR)
- ANNX 0.18
- BACQ 0.00
- MACD
- ANNX 0.00
- BACQ 0.00
- Stochastic Oscillator
- ANNX 19.13
- BACQ 0.00
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About BACQ BLEICHROEDER ACQUISITION CORP. I
Bleichroeder Acquisition Corp I is a blank check company.